Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) saw an uptick in trading volume on Tuesday after Benchmark raised their price target on the stock from $6.00 to $10.00. Benchmark currently has a buy rating on the stock. 1,275,436 shares traded hands during mid-day trading, an increase of 664% from the previous session’s volume of 166,853 shares.The stock last traded at $4.35 and had previously closed at $3.90.

A number of large investors have recently added to or reduced their stakes in the stock. Algert Global LLC boosted its holdings in Harvard Bioscience by 31.0% in the third quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after acquiring an additional 35,276 shares in the last quarter. Granahan Investment Management Inc. MA boosted its holdings in Harvard Bioscience by 80.7% in the third quarter. Granahan Investment Management Inc. MA now owns 537,467 shares of the medical instruments supplier’s stock valued at $2,016,000 after acquiring an additional 240,055 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Harvard Bioscience by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 1,740,790 shares of the medical instruments supplier’s stock valued at $6,528,000 after acquiring an additional 30,068 shares in the last quarter. New York State Common Retirement Fund bought a new stake in Harvard Bioscience in the third quarter valued at $321,000. Finally, Foundry Partners LLC boosted its holdings in Harvard Bioscience by 10.2% in the third quarter. Foundry Partners LLC now owns 754,820 shares of the medical instruments supplier’s stock valued at $2,831,000 after acquiring an additional 70,045 shares in the last quarter. Institutional investors and hedge funds own 61.68% of the company’s stock.

The stock has a market cap of $151.73, a price-to-earnings ratio of -48.33 and a beta of 1.10. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.87 and a current ratio of 3.40.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The business had revenue of $25.05 million during the quarter, compared to analyst estimates of $24.60 million. Harvard Bioscience had a positive return on equity of 1.11% and a negative net margin of 3.16%. sell-side analysts expect that Harvard Bioscience, Inc. will post 0.05 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://theolympiareport.com/2018/01/24/harvard-bioscience-hbio-sees-large-volume-increase-on-analyst-upgrade.html.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.